Search Weight Loss Topics:

Page 21«..10..20212223..3040..»

Home » Hgh » Page 21

Sammy Sosa probably didnt do much to repair his fractured association with the Ricketts family though last nights milquetoast documentary, Long Gone Summer. Though the ESPN 30 for 30 special let us relive that wonderful summer and the home run chase he shared with Mark McGwire, the slugger refused to admit that he specifically did anything to tarnish the game or the organization.

The ownership, they have to understand that Im a humble man, Im not a man to have ego, when I was playing I was a little bit because I was focused on what I was trying to do, Slammin Sammy said. But right now Im gonna be 50 years old. Im a granddaddy, Im a grandparent, so things change. So if I made a mistake, I dont have to say that, but if I made a mistake, I didnt want to offend any body, I dont have a problem with that, Im sorry because you know, I was in my zone.

A film dedicated specifically to Sosa would probably be more fascinating than last nights special. I found the part about his upbringing amidst impoverished conditions in the Dominican Republic one of the films finer moments. Short of Ernie Banks, Fergie Jenkins, Billy Williams, Ron Santo, Ryne Sandberg, and Kerry Wood, few players have been as beloved to Cubs fans in the history of the franchise.

No player from that era has had to specifically answer questions about PED use. Heck, Barry Bonds, who could be the poster boy for HGH, has been welcomed back by the Giants. Even lex Rodrguez, a repeat offender, is protected by at least a thin layer of immunity from the sport and the teams he played for.

The New York Times reported in 2009 Sosa was one of 104 MLB players in 2003 to test positive for PEDs, the results of which were supposed to have been sealed. Nobody has seen the results except for the league, federal agents who seized the documents, and the author of the article, Michael S. Schmidt. In fact, the veracity of that report and the source of its information have been questioned more than once. Additionally, no players or coaches from that era of Cubs baseball have come forth with a statement offering any proof that Sosa was juicing.

Sosa himself has refused to admit guilt despite the leak. When asked in March 2005 under oath before a government committee investigating the illegal use of steroids in the game, the right fielder added To be clear, I have never taken illegal performance-enhancing drugs. I have never injected myself or had anyone inject me with anything.

He was never pursued on charges he may have perjured himself.

I dont know exactly what Tom Ricketts needs to hear from Sosa to end the sluggers exile, but if he is looking for an admission that the energetic right fielder took illegal substances, its not coming. The Cubs chairman has made it clear that he wants his pound of flesh and thats probably not going to change after last nights special.

Why do they worry about me when pretty much everybody in that era did [steroids]? Sosa said in the documentary.

Though the teams all-time home run leader believes he will make a triumphant return to the franchise and fanbase that lovingly adored him for the better part of 13 seasons, it would seem only a change in ownership will provide such an occasion.

What I dont like is taking the blame for [everybody] else. That was a year that we had to do what we had to do. I feel [grateful] to the Chicago Cubs, they gave me the opportunity to be the player that I was.

Cubs News & Notes

Apropos of Nothing

These were my personal top five jams of 1998, heavily influenced by my girlfriend at the time, who always had control of my stereo wherever we drove. In reality, I was mostly into John Cougar Mellencamp, Tom Petty, and Matchbox 20 at the time, with a little Bruce Springsteen tossed in for good measure.

Odds & Sods

ESPN continues to ignore the White Sox, which may have been the best thing about Long Gone Summer.

MLB News & Notes

With owners continually sticking to the same script when it comes to player salaries, negotiations have been utterly ridiculous.

Rob Manfred will never put the game ahead of its owners, and the league statement regarding current negotiations proves that.

The league announced a $2 billion partnership with Turner Sports over the weekend.

The players are refusing to counter the leagues latest proposal, and have demanded that Manfred provide information on restarting the season today.

There was a great deal of intrigue during the 1998 season, but all of it, including the World Series, was overshadowed by Sosa-McGwire.

Joe Torre said his 98 Yankees team never got the credit they deserved. New York won 114 games that season and went 11-2 in the playoffs, including a sweep of the Padres in the World Series.

Extra Innings

A nice gesture by the organization but I hope they remember that millions of Cubs fans worldwide joined into this crazy family of ours just because of #21.

Sliding Into Home

Its important to remember that the position of commissioner in baseball has always been built on the premise that the person in charge be a stooge for ownership. From Kenesaw Mountain Landis to Manfred, any commissioner who has exclusively sided with baseballs land owners has enjoyed longevity in the position. The lone exceptions were Bart Giamatti, who died 154 days after accepting the gig, and Fay Vincent, who was forced from the position after three seasons in 1992 for being too accommodating to players.

They Said It

Monday Walk Up Song

Stay (Wasting Time) by Dave Matthews Band I watched the entire documentary last night, an in retrospect, I could have made much better use of the two hours. As far as todays song, I went to my first DMB concert in 1998. I was promised that as a Grateful Dead fan I would see and hear many similarities. That was a lie, but I had a good time anyway.

Read more:
The Rundown: Long Gone Summer Yawn-Inducing, Sosa Refuses Admission of Guilt, White Sox Erased Again, Players Refuse Further Negotiations -...

Akaroa in Canterbury has recorded its highest ever June temperature after reaching 23C today, according to NIWA Weather.

Akaroa. Source: istock.com

It was a warm winters day across Canterbury, with Christchurch reaching 22.6C, a high it shared with Kaikura.

Christchurch has an average high in June of 11 degrees.

One Christchurch resident told 1 NEWS she was able to wear a t-shirt all day.

The warm temperatures across the region were caused by a north-westerly flow coming across the Tasman, 1 NEWS meteorologist Dan Corbett said.

Cheviot, north of Christchurch, reached 22.7C while Rangiora had a high of 22.1C.

The warm temperatures wont last with an incoming surge of cold behind tomorrows front forecast to bring 5-20cm of snow for parts of the inland hgh country of Canterbury above 500m.

Ski fields in the area, including Mt Hutt, Lyford and Porters, could see even more snow.

Go here to see the original:
Akaroa records its highest ever June temperature after reaching 23C today - 1News

Los Angeles, United State: QY Research recently published a research report titled, Global Infrared Search and Track (IRST) Equipment Market Research Report 2020 The research report is collated on the basis of historic and forecast data derived by using primary and secondary methodologies by researchers. The global Infrared Search and Track (IRST) Equipment market is one of the fastest-growing markets and is expected to witness substantial growth in the forecast years. Reader are provided easy access to thorough analysis on the various aspects such as opportunities and restraints affecting the market. The Infrared Search and Track (IRST) Equipment report clearly explains the trajectory this market will take in the forecast years.

The Infrared Search and Track (IRST) Equipment research report has presented an analysis of various factors influencing the markets current growth. Drivers, restraints, and trends are elaborated to understand their positive or negative effects. This Infrared Search and Track (IRST) Equipment report section is aimed at providing readers with a thorough information about the potential scope of various applications and segments. These estimates are based on the current trends and historic milestones.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)@https://www.qyresearch.com/sample-form/form/1760947/covid-19-impact-on-infrared-search-and-track-irst-equipment-market

This section of the Infrared Search and Track (IRST) Equipment report offers a thorough and comprehensive information about the various manufacturers in the market. The major manufacturers covered in the report hold significant share that demands a microscopic look. It provides vital information about various strategies implemented by these manufacturers to combat competition and expand their footprint in the Infrared Search and Track (IRST) Equipment market. It also surveys the current trends adopted by the manufacturers to innovate their product for the future. This Infrared Search and Track (IRST) Equipment report is structured in such a way so as to help the reader understand the market and make business decisions accordingly.

Key Players Mentioned in the Global Infrared Search and Track (IRST) Equipment Market Research Report:

Lockheed Martin Corporation, Thales Group, Safran S.A., Rheinmetall AG., Leonardo S.p.A., Northrop Grumman Corporation, HGH Systemes Infrarouges SAS, Rheinmetall AG., Aselsan A.S, The Boeing Company

Global Infrared Search and Track (IRST) Equipment Market Segmentation by Product:AirborneNavalLand

Global Infrared Search and Track (IRST) Equipment Market Segmentation by Application:DefenseCivil

The Infrared Search and Track (IRST) Equipment Market research report briefs on segments such as product type and end users. The product type segment gives an understanding about various products available in the Infrared Search and Track (IRST) Equipment market. It also gives information on what is the scope and potential of each product. Also, the segment presents an elaborate information on end users. Understanding end users is of utmost importance as it aids in identifying marketable areas.

Key questions answered in the report: What is the growth potential of the Infrared Search and Track (IRST) Equipment market? Which product segment will grab a lions share? Which regional market will emerge as a frontrunner in coming years? Which application segment will grow at a robust rate? What are the growth opportunities that may emerge in Infrared Search and Track (IRST) Equipment industry in the years to come? What are the key challenges that the global Infrared Search and Track (IRST) Equipment market may face in future? Which are the leading companies in the global Infrared Search and Track (IRST) Equipment market? Which are the key trends positively impacting the market growth? Which are the growth strategies considered by the players to sustain hold in the global Infrared Search and Track (IRST) Equipment market?

Request for customization in Report:@https://www.qyresearch.com/customize-request/form/1760947/covid-19-impact-on-infrared-search-and-track-irst-equipment-market

Table od Content:1.1 Research Scope1.2 Market Segmentation1.3 Research Objectives1.4 Research Methodology1.4.1 Research Process1.4.2 Data Triangulation1.4.3 Research Approach1.4.4 Base Year1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.5.2 Covid-19 Impact: Commodity Prices Indices1.5.3 Covid-19 Impact: Global Major Government Policy1.6 The Covid-19 Impact on Infrared Search and Track (IRST) Equipment Industry1.7 COVID-19 Impact: Infrared Search and Track (IRST) Equipment Market Trends

2 Global Infrared Search and Track (IRST) Equipment Quarterly Market Size Analysis2.1 Infrared Search and Track (IRST) Equipment Business Impact Assessment COVID-192.1.1 Global Infrared Search and Track (IRST) Equipment Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.1.2 Global Infrared Search and Track (IRST) Equipment Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.2 Global Infrared Search and Track (IRST) Equipment Quarterly Market Size 2020-20212.3 COVID-19-Driven Market Dynamics and Factor Analysis2.3.1 Drivers2.3.2 Restraints2.3.3 Opportunities2.3.4 Challenges

3 Quarterly Competitive Assessment, 20203.1 Global Infrared Search and Track (IRST) Equipment Quarterly Market Size by Manufacturers, 2019 VS 20203.2 Global Infrared Search and Track (IRST) Equipment Factory Price by Manufacturers3.3 Location of Key Manufacturers Infrared Search and Track (IRST) Equipment Manufacturing Factories and Area Served3.4 Date of Key Manufacturers Enter into Infrared Search and Track (IRST) Equipment Market3.5 Key Manufacturers Infrared Search and Track (IRST) Equipment Product Offered3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Infrared Search and Track (IRST) Equipment Segments, By Type4.1 Introduction1.4.1 Airborne1.4.2 Naval1.4.3 Land4.2 By Type, Global Infrared Search and Track (IRST) Equipment Market Size, 2019-20214.2.1 By Type, Global Infrared Search and Track (IRST) Equipment Market Size by Type, 2020-20214.2.2 By Type, Global Infrared Search and Track (IRST) Equipment Price, 2020-2021

5 Impact of Covid-19 on Infrared Search and Track (IRST) Equipment Segments, By Application5.1 Overview5.5.1 Defense5.5.2 Civil5.2 By Application, Global Infrared Search and Track (IRST) Equipment Market Size, 2019-20215.2.1 By Application, Global Infrared Search and Track (IRST) Equipment Market Size by Application, 2019-20215.2.2 By Application, Global Infrared Search and Track (IRST) Equipment Price, 2020-2021

6 Geographic Analysis6.1 Introduction6.2 North America6.2.1 Macroeconomic Indicators of US6.2.2 US6.2.3 Canada6.3 Europe6.3.1 Macroeconomic Indicators of Europe6.3.2 Germany6.3.3 France6.3.4 UK6.3.5 Italy6.4 Asia-Pacific6.4.1 Macroeconomic Indicators of Asia-Pacific6.4.2 China6.4.3 Japan6.4.4 South Korea6.4.5 India6.4.6 ASEAN6.5 Rest of World6.5.1 Latin America6.5.2 Middle East and Africa

7 Company Profiles7.1 Lockheed Martin Corporation7.1.1 Lockheed Martin Corporation Business Overview7.1.2 Lockheed Martin Corporation Infrared Search and Track (IRST) Equipment Quarterly Production and Revenue, 20207.1.3 Lockheed Martin Corporation Infrared Search and Track (IRST) Equipment Product Introduction7.1.4 Lockheed Martin Corporation Response to COVID-19 and Related Developments7.2 Thales Group7.2.1 Thales Group Business Overview7.2.2 Thales Group Infrared Search and Track (IRST) Equipment Quarterly Production and Revenue, 20207.2.3 Thales Group Infrared Search and Track (IRST) Equipment Product Introduction7.2.4 Thales Group Response to COVID-19 and Related Developments7.3 Safran S.A.7.3.1 Safran S.A. Business Overview7.3.2 Safran S.A. Infrared Search and Track (IRST) Equipment Quarterly Production and Revenue, 20207.3.3 Safran S.A. Infrared Search and Track (IRST) Equipment Product Introduction7.3.4 Safran S.A. Response to COVID-19 and Related Developments7.4 Rheinmetall AG.7.4.1 Rheinmetall AG. Business Overview7.4.2 Rheinmetall AG. Infrared Search and Track (IRST) Equipment Quarterly Production and Revenue, 20207.4.3 Rheinmetall AG. Infrared Search and Track (IRST) Equipment Product Introduction7.4.4 Rheinmetall AG. Response to COVID-19 and Related Developments7.5 Leonardo S.p.A.7.5.1 Leonardo S.p.A. Business Overview7.5.2 Leonardo S.p.A. Infrared Search and Track (IRST) Equipment Quarterly Production and Revenue, 20207.5.3 Leonardo S.p.A. Infrared Search and Track (IRST) Equipment Product Introduction7.5.4 Leonardo S.p.A. Response to COVID-19 and Related Developments7.6 Northrop Grumman Corporation7.6.1 Northrop Grumman Corporation Business Overview7.6.2 Northrop Grumman Corporation Infrared Search and Track (IRST) Equipment Quarterly Production and Revenue, 20207.6.3 Northrop Grumman Corporation Infrared Search and Track (IRST) Equipment Product Introduction7.6.4 Northrop Grumman Corporation Response to COVID-19 and Related Developments7.7 HGH Systemes Infrarouges SAS7.7.1 HGH Systemes Infrarouges SAS Business Overview7.7.2 HGH Systemes Infrarouges SAS Infrared Search and Track (IRST) Equipment Quarterly Production and Revenue, 20207.7.3 HGH Systemes Infrarouges SAS Infrared Search and Track (IRST) Equipment Product Introduction7.7.4 HGH Systemes Infrarouges SAS Response to COVID-19 and Related Developments7.8 Rheinmetall AG.7.8.1 Rheinmetall AG. Business Overview7.8.2 Rheinmetall AG. Infrared Search and Track (IRST) Equipment Quarterly Production and Revenue, 20207.8.3 Rheinmetall AG. Infrared Search and Track (IRST) Equipment Product Introduction7.8.4 Rheinmetall AG. Response to COVID-19 and Related Developments7.9 Aselsan A.S7.9.1 Aselsan A.S Business Overview7.9.2 Aselsan A.S Infrared Search and Track (IRST) Equipment Quarterly Production and Revenue, 20207.9.3 Aselsan A.S Infrared Search and Track (IRST) Equipment Product Introduction7.9.4 Aselsan A.S Response to COVID-19 and Related Developments7.10 The Boeing Company7.10.1 The Boeing Company Business Overview7.10.2 The Boeing Company Infrared Search and Track (IRST) Equipment Quarterly Production and Revenue, 20207.10.3 The Boeing Company Infrared Search and Track (IRST) Equipment Product Introduction7.10.4 The Boeing Company Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis8.1 Infrared Search and Track (IRST) Equipment Supply Chain Analysis8.1.1 Infrared Search and Track (IRST) Equipment Supply Chain Analysis8.1.2 Covid-19 Impact on Infrared Search and Track (IRST) Equipment Supply Chain8.2 Distribution Channels Analysis8.2.1 Infrared Search and Track (IRST) Equipment Distribution Channels8.2.2 Covid-19 Impact on Infrared Search and Track (IRST) Equipment Distribution Channels8.2.3 Infrared Search and Track (IRST) Equipment Distributors8.3 Infrared Search and Track (IRST) Equipment Customers

9 Key Findings

10 Appendix10.1 About Us10.2 Disclaimer

About Us:QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Visit link:
Infrared Search and Track (IRST) Equipment Market Overview, Growth & Advancement from 2020-2026| Lockheed Martin Corporation, Thales Group, Safran...

Sylvester Stallone might be as responsible for creating the archetype of the jacked action hero as anyone alive. From Rocky to Rambo, Sly was absolutely shredded, hold the cheese. And at well over 70 years old, the movie star is still more diced than a julienne salad.

Perhaps not too shockingly, the septuagenarian may be taking more than his daily dose of Ensure. In 2007, Sly was convicted of smuggling human growth hormone into Australia when customs officials found 48 vials of HGH in his luggage. Investigators witnessed him ditching vials of testosterone off his hotel balcony. Stallone later admitted he was packing an HGH product called Jintropin for an on-location shoot where he needed to look his best. "As you get older, the pituitary gland slows and you feel older, your bones narrow. This stuff gives your body a boost and you feel and look good," he admitted to customs officials according to The Guardian. "Doing Rambo is hard work."

Stallone's ex-wife, former supermodel Janice Dickinson, now mostly known for odd public behavior, claims Sly was sauced all the way back to the '90s and wanted her to share the benefits. "He juiced me. I'd wake up and my arm was as big as Popeye steroids, testosterone, all that stuff," she told Fox News in 2015. Stallone's rep has vigorously denied this outlandish claim and it should be noted injecting steroids does not immediately give you arms like Popeye.

See the original post here:
Celebs who have admitted to using performance enhancing drugs - Nicki Swift

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the infrared aerial camera market and it is poised to grow by USD 362.77 million during 2020-2024, progressing at a CAGR of over 8% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Request for Technavio's latest reports on directly and indirectly impacted markets. Market estimates include pre- and post-COVID-19 impact on the Infrared Aerial Camera Market Download free sample report

The market is concentrated, and the degree of concentration will accelerate during the forecast period. DIAS Infrared GmbH, FLIR Systems Inc., HGH Systemes Infrarouges SAS, Infrared Cameras Inc., InfraTec GmbH, Jenoptik AG, L3Harris Technologies Inc., Leonardo Spa, SZ DJI Technology Co. Ltd., and Yuneec Europe GmbH are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Use of infrared aerial cameras in UAVs has been instrumental in driving the growth of the market.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations. https://www.technavio.com/report/report/infrared-aerial-camera-market-industry-analysis

Infrared Aerial Camera Market 2020-2024: Segmentation

Infrared Aerial Camera Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43022

Infrared Aerial Camera Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The infrared aerial camera market report covers the following areas:

This study identifies incorporation of radiometric technology with infrared aerial cameras as one of the prime reasons driving the infrared aerial camera market growth during the next few years.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Infrared Aerial Camera Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Application

Customer landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Here is the original post:
COVID-19 Impact and Recovery Analysis - Infrared Aerial Camera Market 2020-2024 | Use of Infrared Aerial Cameras in UAVs to Boost Growth | Technavio -...

MARK MCGWIRE TALKED a lot about The Baseball Gods during his playing career, a sure sign of someone who treats the game with a solemnity it doesn't deserve. He was never more publicly grave than during the 1998 season, his finest moment, when he couldn't go three words without reminding everyone how monumentally, crushingly difficult it was to do what he was in the process of doing.

He hit 70 homers that season, destroying a record that had stood for 37 years and setting one that would stand for just three. Outwardly, he enjoyed very few of those homers. After every game, he stood at his locker, gaze trained in the distance, eyes narrowed, a soldier walking point, searching for snipers.

1 Related

"I feel like a caged animal," he said at one point, and even though he was criticized for complaining about something the rest of us were celebrating, he wasn't wrong. There was pressure, and McGwire wore it like a cast-iron overcoat.

I stood in front of that locker after a game more than 20 times that season, and each time McGwire emanated a unique brand of pain. He deflected often, suggesting that we talk to his St. Louis Cardinals teammates, going so far as to point around the room and list their names and contributions, sounding like the world's most dour emcee.

In the 162-episode dramatic series that became the 1998 season, that was McGwire's role: the brooding, team-first giant who just happened to possess a singular skill he never seemed to embrace. He motivated himself by locking the door and pushing the world away.

SAMMY SOSA DID not worship at the altar of The Baseball Gods. He blasted salsa music from a boombox at his locker before games, drowning out whatever was running through the clubhouse speakers (chosen, by decree of TBG, by that day's starting pitcher).

Sosa talked a lot about being the shoeshine boy from the Dominican who hacked his way off the island to smile and hop his way to fame and fortune. He hit bombs and bounced sideways out of the batter's box like he was sliding through a narrow doorway. When he reached home plate, he unleashed an elaborate series of hand gestures that even McGwire found joy in repeating. In 1998, on his way to a 66-homer season that would stand (for three years) as No. 2 in history, Sosa couldn't go more than three words without reminding everyone how much fun it was to do what he was doing.

When McGwire hit No. 62, breaking Roger Maris' single-season record, Sosa was standing in right field in Busch Stadium, and he sprinted from his position to home plate to hug McGwire. Many of his Chicago Cubs teammates fumed at the break with decorum, but in the summer of '98, it was deemed best to shut up and let it ride.

That was Sosa's role: the comic-relief sidekick, assigned to play a simplistic stereotype in service of the man who was preordained to play the lead. He motivated himself by throwing open the door and inviting the world in.

THE HOME RUN is baseball's most violent and spontaneous act. There is an element of defiance, even dismissiveness, in sending a ball over the fence and out of the field of play. And the home run accomplishes everything baseball allegedly doesn't; it creates stars, exposes personalities, generates digestible highlights.

In 1998, McGwire and Sosa engaged in a season-long quest to take down Maris' single-season home run record of 61, a competition that is the subject of "Long Gone Summer," a 30 for 30 documentary premiering Sunday. By July of that season, the home run chase became more than baseballs flying over fences. It was a piece of performance art, a morality play and a precursor for what the game would become. This was the beating heart of baseball's steroid era, and it's clear there was something stronger than wholesome Midwest air and good old-fashioned momentum coursing through the veins of the two men captivating the nation. But for the most part, we weren't overly interested in complications. We were along for the ride, and it was a lot of fun.

"I think it's just a fascination with the home run and the power that's come about the last couple of years," McGwire told me at the time. "People are shaking their heads, thinking, 'What's going on here?' They don't understand it."

He understood it, of course, and his understanding was the root of his nearly pathological desire to deflect attention. The paradox is rich: The man Tony La Russa described as a "back-of-the-room guy," whose sole desire was to merge seamlessly into the clubhouse furniture, went to extralegal attempts to set himself apart. He became a human exaggeration and, in the process, elevated himself above everyone in the game.

His teammates were collateral damage, but McGwire was a master of clubhouse diplomacy. He constantly apologized to his teammates for the imposition, and he followed every milestone homer -- 60, 61, 62, 70 -- by signing a box of a dozen baseballs for each teammate.

Still, there were so many media members in the Cardinals' clubhouse over the final two months of the season; every day it felt like a convention. We soon ferreted out McGwire's closest friends on the team, and we created separate groups in our minds: those who wanted to talk about McGwire; those who would talk about McGwire but didn't particularly enjoy it; and those who wanted nothing to do with any of it.

After one game, there was a crowd of 20 to 30 reporters surrounding catcher Tom Lampkin, whose friendship with McGwire and overall conviviality made him a regular stop on the Tour of Lockers. As Lampkin spoke, he was interrupted by pitcher Kent Mercker, who was hollering from across the room. "Hey, Tom," Mercker called out. "Your house burn down or something?" Lampkin shrugged and laughed, and Mercker threw his hands up and said, "This is nuts. That dude didn't even play today."

BEFORE 1998, Sammy Sosa had successive years of 36, 40 and 36 home runs. Before 1998, Sammy Sosa drove in more than 100 runs in each of those three years. In 1995, Sammy Sosa hit 36 home runs, drove in 119 runs and stole 34 bases, achieving just the 22nd 30-homer, 30-steal season in the history of baseball.

Sammy Sosa was a star. Sammy Sosa got MVP votes. And yet, in "Long Gone Summer," McGwire says of Sosa, "I knew he was a player in our league." McGwire didn't know anything more about him until he hit 20 homers in June.

Those 20 homers created a home run race that nobody saw coming. McGwire was coming off a 58-homer 1997 season, and '98 was set up to be a season-long coronation. The difficulty of hitting 62 homers was acknowledged -- savagely, onerously, gruesomely difficult -- but it was considered McGwire's fate. Somehow, Sosa barged in, kissing his fingertips and bombing out to his spot in right field at Wrigley on a dead sprint as if he couldn't bear the thought of wasting a split second of the adulation awaiting him.

By July, they were co-stars. And when the Cubs and Cardinals played a two-game series in St. Louis on Sept. 7 and 8, the two were being driven on a golf cart -- with police officers jogging behind, like a bizarre scene out of North Korea -- to a joint news conference near the right-field corner of Busch Stadium. McGwire had 60 homers, Sosa 58, but the scene was engineered to make them seem like summer-ball buddies rather than intradivisional competitors. They sat together and played their ascribed roles. Sosa served as a shield, laughing and joking and cajoling McGwire to see slivers of light amid the darkness. He was credited with lifting some of the pressure from McGwire's shoulders and bringing out the big man's lighter side. He also pushed him, because beating Roger Maris had become secondary to beating Sammy Sosa.

THERE IS AN entire language unique to the baseball cheat. You still have to put in the work. (True, but it's far easier when the body is chemically engineered to recover quicker.) Steroids don't help hand-eye coordination. (HGH has been proved to help eyesight, though.) PEDs can't make a bad hitter great. (No, but if you're good at it to begin with, it definitely helps.) La Russa was fluent in this language. McGwire was too.

"Everyone looks at my body," McGwire told me in '98, "but I use my mind more than my arms."

McGwire never had to answer the tough questions that season. There was one scare, the andro scare, when a reporter from The Associated Press wrote about a bottle of androstenedione that sat on the top shelf of McGwire's locker. It wasn't a steroid, necessarily, but it was close enough to raise suspicions. More than 20 years of media self-flagellation later -- what should we have known and when should we have known it? -- it's probably accurate to say everyone involved got swept away by the eagerness to believe.

"Long Gone Summer" depicts McGwire as a man who retains his unique ability to blend defiance with ignorance. It wasn't illegal is a standby, as is Everybody was doing it. McGwire subscribes to both philosophies. Major League Baseball has largely forgiven the main characters of that PED era. McGwire, after retreating from public view for several years after his retirement, gave a tearful public apology as a prelude to becoming a hitting coach for three big league teams. Barry Bonds works for the Giants, and Alex Rodriguez might buy the Mets. Bud Selig and Tony La Russa are in the Hall of Fame. And Jose Canseco is free to roam Twitter and run for president on the long-neglected army-of-robots platform. (Finally, someone gets it.)

Sosa, whose thirst for attention wore on his teammates, has paid a higher price. He is not welcome at Cubs games or events, despite carrying the franchise for many of his 13 years with the team. In 1999, the year after the chase, he hit 63 homers, drove in 141 runs and played in 162 games. The team lost 95 games and yet drew more than 2.8 million fans. But in order for Sosa to return to Wrigley Field, owner Tom Ricketts has demanded some form of contrition. If Sosa does not admit to PED use -- and apologize in a manner that suits current club ownership -- he will continue to be shunned.

Setting aside the moral and competitive issues raised by PEDs, for a team owner -- even one who entered the game after 1998 -- to demand contrition is laughable to the point of insult. For all the shadings and half-truths and outright lies of the steroid era, consensus can be found in the following five words: Ignorance was incentivized and monetized. The landing spot of McGwire's 70th home run -- slightly above and behind the left-field bullpen at Busch Stadium, hardly Class A real estate -- was quickly transformed into Suite 70. It was sold out for every game in 1999, with 70 seats at $70 apiece, nearly $400,000 a year. Nobody apologized for accepting money that was predicated on an alleged fraud.

Baseball history can be plotted through an undefined original sin followed by acts of recidivism and penitence -- maybe unsurprising, given its puritan roots. This pattern can be difficult to follow; McGwire and Sosa supposedly saved the game from the sins of the '94 lockout, three years after Cal Ripken Jr., who broke Lou Gehrig's consecutive-game streak, supposedly saved it from the same sin. It's difficult to say who saved the hardest, and the question itself -- Who saved baseball this time? -- feels as much like an accusation as a compliment, especially now, as the game cracks its knuckles and limbers its neck in preparation for another Category 5 public relations disaster.

There's no question, however, that McGwire and Sosa played a role in changing baseball. The analytical revolution that began in the early 2000s turned home runs from accessories to staples. What was monetized in '98 became institutionalized in less than a generation.

THE MOST MEMORABLE moment in "Long Gone Summer" is so subtle it can't be accidental. As the homers begin to blur into a mlange of hypertrophic forearms and dumbfounded pitchers, McGwire is shown hitting a tape-measure shot against the San Francisco Giants. To this point, every teammate and opponent has practically dripped admiration for McGwire. He's special, he's humble, he's the big redheaded American ideal. Nobody, it seems, can get enough of McGwire.

But as he's rounding the bases on this particular home run against this particular team, we get a glimpse of the particular brand of salvation created by the summer of '98. The camera shows Barry Bonds standing in the outfield. It lasts barely a second, but that's plenty. This is the thin, fast, mustachioed Barry Bonds, the guy who was the most complete player in baseball for the entire decade of the '90s, and he's standing out there with his arms folded. The look on his face is both disgusted and satisfied. He's the detective who just bore through the lies to solve a gruesome crime.

You can track a couple of decades of baseball history in that look. Knowing what Bonds knew then, and what McGwire knew then -- and what the rest of us would soon find out -- you can pretty much read what was going on behind his raised eyebrows:

If this is how it's going to be, fine. Everybody buckle up.

Continued here:
Sammy Sosa, Mark McGwire and what we should have known - ESPN

MIAMI, June 09, 2020 (GLOBE NEWSWIRE) -- Following last Octobers announcement of successful results of the global Phase 3 study of once-weekly somatrogon, an investigational agent for the treatment of pediatric growth hormone deficiency (pGHD), OPKO Health Inc. (OPK) announced today that the Japan Phase 3 clinical trial met its primary and secondary objectives, and demonstrated that the efficacy and safety of somatrogon administered weekly was comparable to GENOTROPIN (somatropin) for injection administered once-daily as measured by annual height velocity after 12 months of treatment in treatment-nave Japanese pre-pubertal children with GHD. The findings were consistent with the results previously reported in the Phase 3 global study.

Using the Full Analysis Set, the least squared means for the annual height velocity was higher in the somatrogon group (9.65 cm/year) than in the GENOTROPIN group (7.87 cm/year). The point estimate of the treatment difference was 1.79 cm/year with the two-sided 95% confidence interval of (0.97, 2.60). Similarly, greater change in height standard deviation score from baseline at 12 months was observed for the somatrogon group (0.94) compared to the GENOTROPIN group (0.52), indicating that both somatrogon and GENOTROPIN were associated with catch-up growth in treated patients.

Most adverse events were mild to moderate in severity with no notable differences between the treatment groups, and weekly somatrogon administration was generally well-tolerated. A total of six serious adverse events were reported in four patients (two in the somatrogon arm and two in the GENOTROPIN arm). One patient in the GENOTROPIN group discontinued treatment in the study due to adverse events.

We are pleased to announce positive top-line results from the Japanese Phase 3 clinical study of somatrogon. We have reached an additional clinical development milestone of somatrogon with the demonstration of comparable efficacy and safety of somatrogon administered once-weekly to daily administration of GENOTROPIN in pediatric patients with growth hormone deficiency, said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. Positive results in both the Japanese and pivotal global Phase 3 pediatric trials are promising for children with pGHD. Treatment with once-weekly somatrogon represents a significant advance, which has the potential to enhance patient adherence and quality of life.

The data from the Japan Phase 3 trial are very encouraging and point to the potential of bringing a once-weekly treatment option to children with pGHD. We are committed to furthering treatment advances for people living with rare growth hormone disorders and this is an exciting advance that may help ease the daily disease burden for children and their caregivers, said Brenda Cooperstone, M.D., Chief Development Officer, Rare Disease, Pfizer Global Product Development.

In 2014, Pfizer and OPKO entered into a worldwide agreement for the development and commercialization of somatrogon for the treatment of GHD. Under the agreement, OPKO is responsible for conducting the clinical program and Pfizer is responsible for registering and commercializing the product. The companies will evaluate the potential for additional pediatric and adult indications, as appropriate.

About the Study

The Phase 3 study of somatrogon in 44 treatment-nave Japanese pre-pubertal children with pGHD was a 12-month, open-label, randomized, active-controlled, parallel-group study of the efficacy and safety of weekly somatrogon compared to recombinant human growth hormone (r-hGH), GENOTROPIN (somatropin) for injection treatment administered once-daily. Eligible patients were randomized in a 1:1 ratio to receive either once-weekly somatrogon or GENOTROPIN administered once-daily (reference therapy, 0.025 mg/kg/day which is equivalent to 0.175 mg/kg/week). To obtain pharmacokinetic information of three different weekly doses in Japanese pGHD patients, somatrogon treated patients received 0.25 mg/kg/week for 2 weeks, followed by 0.48 mg/kg/week for 2 weeks followed by 0.66 mg/kg/week for the remaining 46 weeks. Somatrogon was administered subcutaneously using a single patient use, multi-dose, disposable, pre-filled pen, the same pen used in the global study, while GENOTROPIN was administered using approved commercial products in Japan.

Story continues

Patients who completed the 12-month Main Study Period and met the inclusion criteria were given the opportunity to continue in a long-term open label extension period with once-weekly somatrogon until marketing approval. All patients in the GENOTROPIN group have been switched to weekly somatrogon treatment.

About Somatrogon

Somatrogon is a new molecular entity that contains the natural sequence of human growth hormone and one copy of the C-terminal peptide (CTP) from the beta chain of human chorionic hCG at the N-terminus and two copies at the C-terminus. The CTPs extend the half-life of the molecule. Somatrogon received Orphan Drug designation in the U.S. and the EU for the treatment of children and adults with growth hormone deficiency.

About Growth Hormone Deficiency

Growth hormone deficiency is a rare disease characterized by the inadequate secretion of growth hormone from the pituitary gland and affects one in approximately 4,000 to 10,000 people. In children, this disease can be caused by genetic mutations or acquired after birth. Because the patient's pituitary gland secretes inadequate levels of somatropin, the hormone that causes growth, his or her height may be affected and puberty may be delayed. Without treatment, he or she will have persistent growth attenuation, a very short height in adulthood and may experience other health problems.

About GENOTROPIN

GENOTROPIN is a recombinant growth hormone as a replacement treatment option, approved in the United States for children who do not make enough growth hormone on their own, have the genetic condition called Prader-Willi syndrome (PWS), were born smaller than most other babies, have the genetic condition called Turner syndrome (TS) or have idiopathic short stature (ISS). GENOTROPIN is also approved in the United States to treat adults with growth hormone deficiency. GENOTROPIN is taken by injection just below the skin and is available in a wide range of devices to fit a range of individual dosing needs. GENOTROPIN is distributed by Pharmacia and Upjohn Co., a division of Pfizer, Inc.

About OPKO Health, Inc.

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit http://www.opko.com.

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information about a product candidate, somatrogon dosed once-weekly in pre-pubertal children with growth hormone deficiency (or GHD), including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications may be filed in any jurisdictions for somatrogon; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether somatrogon will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of somatrogon; and competitive developments.

A further description of risks and uncertainties can be found in OPKOs Annual Reports on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors, Forward-Looking Information and Factors That May Affect Future Results, Cautionary Statement Regarding Forward-Looking Statements, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at http://www.sec.govand http://www.OPKO.com.

Contacts:

LHA Investor RelationsYvonne Briggs, 310-691-7100ybriggs@lhai.com orBruce Voss, 310-691-7100bvoss@lhai.com

The rest is here:
OPKO Health Announces Positive Top-Line Results of Phase 3 Efficacy and Safety Study of Somatrogon for the Treatment of Japanese Children with Growth...

The research study on Global Hormone Replacement Therapy market 2019 presents an extensive analysis of current Hormone Replacement Therapy market size, drivers, trends, opportunities, challenges, as well as key Hormone Replacement Therapy market segments. Further, it explains various definitions and classification of the Hormone Replacement Therapy industry, applications, and chain structure.In continuation of this data, the Hormone Replacement Therapy report covers various marketing strategies followed by key players and distributors. Also explains Hormone Replacement Therapy marketing channels, potential buyers and development history. The intent of global Hormone Replacement Therapy research report is to depict the information to the user regarding Hormone Replacement Therapy market forecast and dynamics for the upcoming years. The Hormone Replacement Therapy study lists the essential elements which influence the growth of Hormone Replacement Therapy industry. Long-term evaluation of the worldwide Hormone Replacement Therapy market share from diverse countries and regions is roofed within the Hormone Replacement Therapy report. Additionally, includes Hormone Replacement Therapy type wise and application wise consumption figures.

The Final Report will cover the impact analysis of COVID-19 on this industry.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225607

After the basic information, the global Hormone Replacement Therapy Market study sheds light on the Hormone Replacement Therapy technological evolution, tie-ups, acquisition, innovative Hormone Replacement Therapy business approach, new launches and Hormone Replacement Therapy revenue. In addition, the Hormone Replacement Therapy industry growth in distinct regions and Hormone Replacement Therapy R;D status are enclosed within the report.The Hormone Replacement Therapy study also incorporates new investment feasibility analysis of Hormone Replacement Therapy. Together with strategically analyzing the key micro markets, the report also focuses on industry-specific drivers, restraints, opportunities, and challenges in the Hormone Replacement Therapy market.

View Source of RelatedReports :

Hormone Replacement Therapy Market

Natural Killer (NK) Cell Therapeutics Market

Genomics Market

Bioinformatics Market

Pharmacogenomics Market

Genome Engineering Market

Global Hormone Replacement Therapy Market Segmentation 2019: Hormone Replacement TherapyThe study also classifies the entire Hormone Replacement Therapy market on basis of leading manufacturers, different types, various applications and diverse geographical regions. Overall Hormone Replacement Therapy market is characterized by the existence of well-known global and regional Hormone Replacement Therapy vendors. These established Hormone Replacement Therapy players have huge essential resources and funds for Hormone Replacement Therapy research as well as developmental activities. Also, the Hormone Replacement Therapy manufacturers focusing on the development of new Hormone Replacement Therapy technologies and feedstock. In fact, this will enhance the competitive scenario of the Hormone Replacement Therapy industry.

The Leading Players involved in global Hormone Replacement Therapy market are:

By Therapy Type (Human Growth Hormone (HGH) Replacement Therapy, Testosterone Replacement Therapy, Thyroid Replacement Therapy, Estrogen Replacement Therapy)

By Application (Growth Hormone Deficiency,Menopause, Hypothyroidism, Male Hypogonadism, and Others)

By Route of Administration (Oral, Parenteral, and Others)

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) 

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa )

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225607

Worldwide Hormone Replacement Therapy Market Different Analysis:Competitors Review of Hormone Replacement Therapy Market: Report presents the competitive landscape scenario seen among top Hormone Replacement Therapy players, their company profile, revenue, sales, business tactics and forecast Hormone Replacement Therapy industry situations. Production Review of Hormone Replacement Therapy Market: It illustrates the production volume, capacity with respect to major Hormone Replacement Therapy regions, application, type, and the price. Sales Margin and Revenue Accumulation Review of Hormone Replacement Therapy Market: Eventually explains sales margin and revenue accumulation based on key regions, price, revenue, and Hormone Replacement Therapy target consumer. Supply and Demand Review of Hormone Replacement Therapy Market: Coupled with sales margin, the report depicts the supply and demand seen in major regions, among key players and for every Hormone Replacement Therapy product type. Also interprets the Hormone Replacement Therapy import/export scenario. Other key reviews of Hormone Replacement Therapy Market: Apart from the above information, correspondingly covers the company website, number of employees, contact details of major Hormone Replacement Therapy players, potential consumers and suppliers. Also, the strengths, opportunities, Hormone Replacement Therapy market driving forces and market restraints are studied in this report.

Highlights of Global Hormone Replacement Therapy Market Report:* This report provides in detail analysis of the Hormone Replacement Therapy and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2019 ; 2029. * It also elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for world Hormone Replacement Therapy market. * This study also provides key insights about Hormone Replacement Therapy market drivers, restraints, opportunities, new product launches, approvals, regional outlook, and competitive strategies adopted by the leading Hormone Replacement Therapy players. * It profiles leading players in the worldwide Hormone Replacement Therapy market based on the following parameters ; company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans. * Insights from Hormone Replacement Therapy report would allow marketers and management authorities of companies to make an informed decision with respect to their future product launches, market expansion, and Hormone Replacement Therapy marketing tactics. * The world Hormone Replacement Therapy industry report caters to various stakeholders in Hormone Replacement Therapy market. That includes investors, device manufacturers, distributors and suppliers for Hormone Replacement Therapy equipment. Especially incorporates government organizations, Hormone Replacement Therapy research and consulting firms, new entrants, and financial analysts. *Various strategy matrices used in analyzing the Hormone Replacement Therapy market would provide stakeholders vital inputs to make strategic decisions accordingly.

Global Hormone Replacement Therapy Market Report Provides Comprehensive Analysis of Following: ; Hormone Replacement Therapy Market segments and sub-segments ; Industry size ; Hormone Replacement Therapy shares ; Hormone Replacement Therapy Market trends and dynamics ; Market Drivers and Hormone Replacement Therapy Opportunities ; Supply and demand of world Hormone Replacement Therapy industry ; Technological inventions in Hormone Replacement Therapy trade ; Hormone Replacement Therapy Marketing Channel Development Trend ; Global Hormone Replacement Therapy Industry Positioning ; Pricing and Brand Strategy ; Distributors/Traders List enclosed in Positioning Hormone Replacement Therapy Market.

Request For Full Report:https://www.kennethresearch.com/sample-request-10225607

Moreover, the report organizes to provide essential information on current and future Hormone Replacement Therapy market movements, organizational needs and Hormone Replacement Therapy industrial innovations. Additionally, the complete Hormone Replacement Therapy report helps the new aspirants to inspect the forthcoming opportunities in the Hormone Replacement Therapy industry. Investors will get a clear idea of the dominant Hormone Replacement Therapy players and their future forecasts.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth ResearchEmail: [emailprotected]Phone: +1 313 462 0609

Here is the original post:
Hormone Replacement Therapy Market Outlook By Industry Size, Share, Revenue, Regions And Top Key Players Analysis From 2020-2029 - Jewish Life News

The NBA has tested its players for human growth hormone since the 2015-16 season, and a number of players have been suspended for its use over the past several years. This season, John Collins was suspended after testing positive for Peptide-2, which releases growth hormone, but if Dallas Mavericks owner Mark Cuban had his way, that wouldn't have been the case.

On Thursday, the University of Michigan released a study claiming that HGH could aid in the recovery of torn ACLs by preventing the loss of muscle strength in knees. Cuban funded that study, and went on to argue on its behalf on Twitter.

"It's time to recognize that HGH (Human Growth Hormone) can positively impact injury recovery," Cuban wrote. "I funded this study so that athletes can get back to full strength and doing what they love."

On an appearance Friday on ESPN's "The Jump,"Cuban argued that the only reason HGH is banned by the NBA is because the World Anti-Doping Association banned it.

"There really was no research or complete logic for doing it," Cuban said. "So a couple of years ago, I said, 'look, if there's no data there to dismiss HGH, let's find out if it can help for injury recovery because it's been discussed as having that ability.' So I worked with the University of Michigan and we put together a study, and as it turned out, comparing athletes vs. a placebo, there was a significant improvement in their recovery time and getting back to full strength. And so now, this is the first step towards offering data and hopefully the NBA, the Olympics and other leagues will look at this and say 'let's do some more studies.' I'm willing to get involved with more studies financially, but if we can get the leagues to do it, the players I think will all be for it as long as you can prove that it's safe."

Injury recovery is an especially important topic at the moment in light of the impact coronavirus has had on professional sports. The NBA has now spent over two months on hiatus, and with July 31 as the target date for a return, games will have been suspended for over four months before resuming. The NBA is scrambling to figure out a training camp format to help get players back into shape before beginning games again, but there is no substitute for the work that goes into a normal season.

If HGH could help players recover from injuries suffered in the aftermath of the shutdown or potentially prevent those injuries from coming in the first place, it is an option that should at least be explored. As long as it is safe, keeping players healthy will always be a priority for the NBA.

Read more here:
Mark Cuban supports use of HGH in injury recovery, funded study with University of Michigan on subject - CBS Sports

After careful consideration, the Endocrine Society canceled its annual meeting (ENDO 2020), which was set to take place in San Francisco, California, from March 28 to 31, 2020, because of concerns regarding coronavirus disease 2019 (COVID-19). Research findings that were scheduled to be presented at the meeting have been published in a supplemental issue of the Journal of the Endocrine Society.

The society is hosting ENDO Online, a complimentary virtual event featuring on-demand and live programming, from June 8 to 22, 2020, to provide a platform for continued learning and research exhibition. For more information, visit the Endocrine Societys website.

Switching from daily human growth hormone (hGH; somatropin) therapy to once-weekly TransCon hGH resulted in a similar safety and efficacy profile in children and adolescents, according to study results intended to be presented at the annual meeting of the Endocrine Society (ENDO 2020).

Once-weekly TransCon hGH, an investigational long-acting prodrug consisting of hGH, an inert protective carrier, and a linker that temporarily binds them, was assessed in the phase 3 Flight trial (ClinicalTrials.gov Identifier: NCT03305016).

The study aimed to assess the safety, tolerability, and efficacy of once-weekly hGH over 26 weeks. The main efficacy outcomes were annualized height velocity, height standard deviation score (SDS), and insulinlike growth factor-1 (IGF-1) SDS.

The study cohort included 146 participants aged 1 to 17 years (mean age, 10.6 years) who were treated with open-label once-weekly TransCon hGH at dose of 0.24 mg/kg. Most patients had previously received treatment with daily hGH and only 3 were treatment naive.

Treatment-emergent adverse events were documented in 56.8% patients, but only 4.1% experienced an event that was considered to be related to the study drug. The type and frequency of the treatment-emergent adverse events were in line with the known safety profile of daily hGH and none led to discontinuation of the study drug. Although low-titer anti-hGH binding antibodies were detected in 2.8% of treated patients, no neutralizing antibodies were detected.

At 26 weeks, the least-squares mean annualized height velocity was 8.7 cm/y (95% CI, 8.2-9.2) and the least-squares mean height SDS change from baseline was +0.25 (95% CI, 0.21-0.29). The mean observed annualized height velocity ranged from 8.2 to 16.2 cm/y and mean observed height SDS change ranged from +0.23 to +0.96.

In accordance with previous trials in treatment-naive patients, the linear association between average IGF-1 SDS and TransCon hGH doses was also evident in this cohort of children with prior daily hGH treatment who had dose titrations.

Overall, comparing the daily vs weekly treatment regimens, the researchers concluded that TransCon hGH treatment outcomes, including [annualized height velocity] and height SDS, were as expected across a diversity of ages, disease characteristics, and treatment experiences, reflective of a real-world setting. Dose titrations of TransCon hGH demonstrated a predictable IGF-1 response.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Maniatis AK, Nadgir U, Saenger P, et al. Phase 3 FliGHt trial: experience of switching from daily growth hormone therapy to once-weekly TransCon hGH in children with growth hormone deficiency. J Endocr Soc. 2020;4(suppl 1):OR10-05.

Link:
How Does the Switch From Daily to Weekly Dosing Affect Growth Hormone Therapy Outcomes? - Endocrinology Advisor

Page 21«..10..20212223..3040..»

Home » Hgh » Page 21